LobbyingTris Pharma, Inc. and Its Wholly Owned Subsidiary Adneuris Therapeutics Fka Tris lobbying by quarter
Tris Pharma, Inc. and Its Wholly Owned Subsidiary Adneuris Therapeutics Fka Tris's latest lobbying report covers Q2 2026, at $50K. The four quarters Q4 2025–Q3 2026 total $150K. Its first report covers Q3 2024; the issues it reports most are Pharmacy.
Tris Pharma, Inc. and Its Wholly Owned Subsidiary Adneuris Therapeutics Fka Tris
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $150K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q3 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q3 2024 | $50K | 1 |
| Q4 2024 | $50K | 1 |
| Q1 2025 | $50K | 1 |
| Q2 2025 | $50K | 1 |
| Q3 2025 | $50K | 1 |
| Q4 2025 | $50K | 1 |
| Q1 2026 | $50K | 1 |
| Q2 2026 | $50K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$400K · 8 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES8 reports
- SENATE8 reports
- Natl Highway Traffic Safety Administration (NHTSA)5 reports
Firms it paid
| Firm | ||
|---|---|---|
| Aegis | $400K | 8 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ANNE ELIZABETH ESPOSITO | Health Policy Coordinator, Energy and Commerce Committee; Health Policy Advisor, Health Subcommittee (Chairman Bilirakis) | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/02for Q2 | Aegis | $50K |
| 04/07for Q1 | Aegis | $50K |
| 01/12for Q4 2025 | Aegis | $50K |
| 25/10/10for Q3 2025 | Aegis | $50K |
| 25/07/18for Q2 2025 | Aegis | $50K |
| 25/04/04for Q1 2025 | Aegis | $50K |
| 25/01/16for Q4 2024 | Aegis | $50K |
| 24/10/03for Q3 2024 | Aegis | $50K |
| 24/07/23for Q3 2024 | Aegis | Under $5,000 |